Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NEXST
- Sponsors Bayer
- 11 Jul 2016 Status changed from active, no longer recruiting to completed.
- 27 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Mar 2014 Planned end date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.